![[Updated] B-2 Spirit Bombers Struck Iranian Nuclear Sites](https://theaviationist.com/wp-content/uploads/2025/06/B2sGuam_2.jpg)
STAT+: Eli Lilly drug preserves lean mass in patients losing weight on Wegovy
Some doctors are concerned that patients taking weight loss drugs like Wegovy may be losing too much lean mass. A combination therapy might change that.
CHICAGO — An investigational therapy from Eli Lilly helped preserve lean mass and drive greater loss of fat in patients taking the popular obesity treatment Wegovy.
In a Phase 2 trial, patients taking the highest-dose combination of Wegovy and the drug, called bimagrumab, lost 22% of their weight at 72 weeks. Ninety-three percent of that was fat mass, and the rest was lean mass. People taking Wegovy alone lost a smaller 16% of their weight, and 72% of that was fat mass, according to results that will be presented Monday at the American Diabetes Association meeting.
Patients taking the combination experienced an estimated 58% reduction in visceral fat, the type of fat in the abdomen that’s thought to be particularly harmful. That compares with a drop of 36% in those taking Wegovy alone.
